epidemic parotitis

流行性耳下腺炎

WordNet

1. (especially of medicine) of disease or anything resembling a disease; attacking or affecting many individuals in a community or a population simultaneously; "an epidemic outbreak of influenza"
2. a widespread outbreak of an infectious disease; many people are infected at the same time
3. inflammation of one or both parotid glands

PrepTutorEJDIC

1. (病気などが)『伝染性の』,急速に広がる / (一般に)流行している / (一時的な)流行病,伝染病 / 流行,はやり

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/04/21 17:54:08」(JST)

wiki en

[Wiki en表示]

For other uses of the word mumps, see Mumps (disambiguation).

Mumps
Child with mumps
Classification and external resources
Specialty	Infectious disease
ICD-10	B26
ICD-9-CM	072
DiseasesDB	8449
MedlinePlus	001557
eMedicine	emerg/324 emerg/391 ped/1503
Patient UK	Mumps
MeSH	D009107

Mumps, also known as epidemic parotitis, is a viral disease caused by the mumps virus. Initial signs and symptoms often include fever, muscle pain, headache, and feeling tired. This is then usually followed by painful swelling of one or both parotid glands. Symptoms typically occur 16 to 18 days after exposure and resolve after 7 to 10 days. Symptoms in adults are often more severe than in children. About a third of people have mild or no symptoms. Complications may include infections of the covering of the brain (15%), pancreatitis (4%), permanent deafness, and painful testicular swelling which uncommonly results in infertility. Women may develop ovarian swelling but this does not increase the risk of infertility.

Mumps is highly contagious and spreads rapidly among people living in close quarters. The virus is transmitted by respiratory droplets or direct contact with an infected person. Only humans get and spread the disease. People are infectious to each other from about 7 days before the start of symptoms to about 8 days after. After an infection a person is typically immune for life. Reinfection is possible but tends to be mild. Diagnosis is usually suspected due to parotid swelling and can be confirmed by isolating the virus on a swab of the parotid duct. Testing for IgM antibodies in the blood is simple and may be useful; however, can be falsely negative in those who have been immunized.

Mumps is preventable by two doses of the mumps vaccine. Most of the developed world includes it in their immunization programs, often in combination with measles and rubella vaccine. Countries that have low immunization rates may see an increase in cases among older age groups and thus worse outcomes. There is no specific treatment. Efforts involve controlling symptoms with pain medication such as acetaminophen. Intravenous immunoglobulin may be useful in certain complications. Hospitalization may be required if meningitis or pancreatitis develops. About one per ten thousand people who are infected die.

Without immunization about 0.1% to 1% of the population are affected per year. Widespread vaccination has resulted in a more than 90% decline in rates of disease. Mumps is more common in the developing world where vaccination is less common. Outbreaks, however, may still occur in a vaccinated population. Before the introduction of a vaccine, mumps was a common childhood disease worldwide. Larger outbreaks of disease would typically occur every two to five years. Children between the ages of five and nine were most commonly affected. Among immunized population often those in their early 20s are affected. Around the equator it often occurs all year round while in the more Northerly and Southerly regions of the world it is more common in the winter and spring. Painful swelling of the parotid glands and testicles were described by Hippocrates in the 5th century BCE.

Signs and symptoms

Mumps is usually preceded by a set of prodromal symptoms including low-grade fever, headache, and malaise. This is followed by progressive swelling of one or both parotid glands. Parotid gland swelling usually lasts about one week. Other symptoms of mumps can include dry mouth, sore face and/or ears and some patients find it difficult to talk. A vaccine has been available since the 1960s.

Complications

• Painful testicular inflammation develops in 15–40% of men who have completed puberty and contract the mumps virus. This testicular inflammation is generally one-sided (both testicles are swollen in 15–30% of mumps orchitis cases) and typically occurs about 10 days after the parotid gland. Testicular swelling has been documented as late as six weeks after parotid gland swelling. Decreased fertility is an uncommon consequence of testicular inflammation from mumps and infertility is rare.
• Studies have reached differing conclusions regarding whether or not infection with the mumps virus during pregnancy leads to an increased rate of spontaneous abortion.
• Meningitis occurs in up to 10% of cases (40% of cases occur without parotid swelling)
• Ovarian inflammation occurs in about 5% of adolescent and adult females.
• Acute pancreatic inflammation in about 4% of cases, manifesting as abdominal pain and vomiting
• Brain inflammation (very rare, and fatal in about 1% of the cases when it occurs)
• Profound (91 dB or more) but rare sensorineural hearing loss, uni- or bilateral. Acute unilateral deafness occurs in about 0.005% of cases.

Cause

The mumps virus is an enveloped single-stranded, linear negative-sense RNA virus of the Rubulavirus genus and Paramyxovirus family. The genome consists of 15,384 bases encoding nine proteins. Proteins involved in viral replication are the nucleoprotein, phosphoprotein, and polymerase protein while the genomic RNA forms the ribonucleocapsid. Humans are the only natural host for the virus.

Mumps is spread from person to person through contact with respiratory secretions, such as saliva from an infected person. When an infected person coughs or sneezes, the droplets aerosolize and can enter the eyes, nose, or mouth of another person. Mumps can also be spread by sharing eating utensils or cups. The virus can also survive on surfaces and then be spread after contact in a similar manner. A person infected with mumps is contagious from approximately 7 days before the onset of symptoms until about 8 days after symptoms start. The incubation period (time until symptoms begin) can be from 12–25 days, but is typically 16–18 days. 20-40% of persons infected with the mumps virus do not show symptoms, so it is possible to be infected and spread the virus without knowing it.

Diagnosis

During an outbreak, a diagnosis can be made by determining recent exposure and parotitis. However, when the disease incidence is low, other infectious causes of parotitis should be considered such as HIV, coxsackievirus, and influenza. Some viruses such as enteroviruses may cause aseptic meningitis that is very clinically similar to mumps.

A physical examination confirms the presence of the swollen glands. Usually, the disease is diagnosed on clinical grounds, and no confirmatory laboratory testing is needed. If there is uncertainty about the diagnosis, a test of saliva or blood may be carried out; a newer diagnostic confirmation, using real-time nested polymerase chain reaction (PCR) technology, has also been developed. As with any inflammation of the salivary glands, the serum level of the enzyme amylase is often elevated.

Prevention

The most common preventative measure against mumps is a vaccination with a mumps vaccine, invented by American microbiologist Maurice Hilleman at Merck. The vaccine may be given separately or as part of the MMR immunization vaccine that also protects against measles and rubella. In the US, MMR is now being supplanted by MMRV, which adds protection against chickenpox (varicella, HHV3). The WHO (World Health Organization) recommends the use of mumps vaccines in all countries with well-functioning childhood vaccination programmes. In the United Kingdom it is routinely given to children at age 13 months with a booster at 3–5 years (preschool) This confers lifelong immunity. The American Academy of Pediatrics recommends the routine administration of MMR vaccine at ages 12–15 months and at 4–6 years. In some locations, the vaccine is given again between 4 to 6 years of age, or between 11 and 12 years of age if not previously given. The efficacy of the vaccine depends on the strain of the vaccine, but is usually around 80%. The Jeryl Lynn strain is most commonly used in developed countries but has been shown to have reduced efficacy in epidemic situations. The Leningrad-Zagreb strain commonly used in developing countries appears to have superior efficacy in epidemic situations.

Because of the outbreaks within college and university settings, many governments have established vaccination programs to prevent large-scale outbreaks. In Canada, provincial governments and the Public Health Agency of Canada have all participated in awareness campaigns to encourage students ranging from grade 1 to college and university to get vaccinated.

Some anti-vaccine activists protest against the administration of a vaccine against mumps, claiming that the attenuated vaccine strain is harmful, and/or that the wild disease is beneficial. There is no evidence whatsoever to support the claim that the wild disease is beneficial, or that the MMR vaccine is harmful. Claims have been made that the MMR vaccine is linked to autism and inflammatory bowel disease, including one study by Andrew Wakefield. The paper was discredited and retracted in 2010 and Wakefield was later stripped of his license after his work was found to be an "elaborate fraud". Also, subsequent studies indicate no link between vaccination with the MMR and autism. Since the dangers of the disease are well known, and the dangers of the vaccine are quite minimal, most doctors recommend vaccination.

The WHO, the American Academy of Pediatrics, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention, the American Academy of Family Physicians, the British Medical Association and the Royal Pharmaceutical Society of Great Britain currently recommend routine vaccination of children against mumps. The British Medical Association and Royal Pharmaceutical Society of Great Britain had previously recommended against general mumps vaccination, changing that recommendation in 1987.

Before the introduction of the mumps vaccine, the mumps virus was the leading cause of viral meningoencephalitis in the United States. However, encephalitis occurs rarely (less than 2 per 100,000). In one of the largest studies in the literature, the most common symptoms of mumps meningoencephalitis were found to be fever (97%), vomiting (94%) and headache (88.8%). The mumps vaccine was introduced into the United States in December 1967: since its introduction there has been a steady decrease in the incidence of mumps and mumps virus infection. There were 151,209 cases of mumps reported in 1968. From 2001 to 2008, the case average was only 265 per year, excluding an outbreak of >6000 cases in 2006 attributed largely to university contagion in young adults.

Management

There is no available cure for mumps and treatment is supportive. Symptoms may be relieved by the application of intermittent ice or heat to the affected neck/testicular area and by acetaminophen for pain relief. Warm saltwater gargles, soft foods, and extra fluids may also help relieve symptoms. Acetylsalicylic acid (aspirin) is not used to treat children due to the risk of Reye's syndrome.

There is no effective post-exposure recommendation to prevent secondary transmission, nor is the post-exposure use of vaccine or immunoglobulin effective.

Mumps is considered most contagious in the five days after the onset of symptoms, and isolation is recommended during this period. In someone who has been admitted to hospital, standard and droplet precautions are needed. People who work in healthcare cannot work for five days.

Epidemiology

Main article: List of modern mumps outbreaks

References

External links

• NHS.uk – Encyclopedia – 'NHS Direct Online Health Encyclopaedia: Mumps', National Health Service (UK)
• WHO.int – "Immunization, Vaccines and Biologicals: Mumps vaccine", World Health Organisation
• MicrobiologyBytes: Paramyxoviruses"
• cdc.gov – Collection of information from the CDC concerning mumps
• Public Health Agency of Canada – Public Health Agency of Canada Vaccination Campaigns

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. ムンプス mumps
• 2. 黄熱 yellow fever
• 3. 成人における無菌性髄膜炎 aseptic meningitis in adults
• 4. 関節炎の原因となる特定のウイルス specific viruses that cause arthritis
• 5. ウイルス性髄膜炎：小児における臨床的特徴および診断 viral meningitis clinical features and diagnosis in children

English Journal

• One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life.

• Henry O1, Brzostek J2, Czajka H3, Leviniene G4, Reshetko O5, Gasparini R6, Pazdiora P7, Plesca D8, Desole MG9, Kevalas R10, Gabutti G11, Povey M12, Innis B13.
• Vaccine.Vaccine.2018 Jan 8;36(3):381-387. doi: 10.1016/j.vaccine.2017.11.081. Epub 2017 Dec 7.
• PMID 29224964

• Building capacity for active surveillance of vaccine adverse events in the Americas: A hospital-based multi-country network.

• Bravo-Alcántara P1, Pérez-Vilar S2, Molina-León HF3, Sturkenboom M4, Black S5, Zuber PLF6, Maure C6, Castro JL7; L.A.N.V.A.P. (Latin American Network for VAccine Pharmacovigilance).
• Vaccine.Vaccine.2018 Jan 8;36(3):363-370. doi: 10.1016/j.vaccine.2017.04.069. Epub 2017 Aug 10.
• PMID 28803714

• Enhancing global vaccine pharmacovigilance: Proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination.

• Perez-Vilar S1, Weibel D2, Sturkenboom M2, Black S3, Maure C4, Castro JL5, Bravo-Alcántara P6, Dodd CN7, Romio SA8, de Ridder M7, Nakato S7, Molina-León HF9, Elango V10, Zuber PLF4; WHO Global Vaccine Safety-Multi Country Collaboration.
• Vaccine.Vaccine.2018 Jan 8;36(3):347-354. doi: 10.1016/j.vaccine.2017.05.012. Epub 2017 May 27.
• PMID 28558983

Japanese Journal

• 感染管理支援システムを用いた病院職員のウイルス抗体価およびワクチン接種歴情報管理

• 土屋 憲,池ヶ谷 佳寿子,明貝 路子,小路 毅,増田 昌文
• 日本環境感染学会誌 = Japanese journal of environmental infections 26(5), 311-315, 2011-09-26
•   2007年の国内での麻疹の流行に伴い，当院でも病院職員を対象とした麻疹，風疹，水痘および流行性耳下腺炎に対するウイルス抗体価の測定とワクチン接種を開始した．しかし，職員属性情報と抗体価測定データの管理の多くを手作業で行うため担当者の負担は大きく，効率性と正確性に問題があった．2010年，感染管理支援システムの導入に伴い，このような問題点を解消するためにワクチン接種歴の管理を …
• NAID 10030237051

• 五類感染症(定点把握) 流行性耳下腺炎(ムンプス) (新感染症学(下)新時代の基礎・臨床研究) -- (感染症法分類--発症・病態・診断・治療)

• 庵原 俊昭
• 日本臨床 65(-), 380-383, 2007-03
• NAID 40015386817

• 流行性耳下腺炎と化膿性耳下腺炎の2例に関する一考察

• 田中 繁宏,相澤 徹,四元 美帆,小柳 好生,野老 稔
• 武庫川女子大学紀要. 自然科学編 52, 1-3, 2004
• 近年ウイルス感染症の増加に関する報告が多い.流行性耳下腺炎はムンプスウイルスによるもので小児によくみられる全身性の疾患で,耳下腺が腫脹する.髄膜炎,膵炎,睾丸炎などを呈する.鑑別診断は反復性耳下腺炎,頚部リンパ節炎,化膿性耳下腺炎である.我々は青春期発症の化膿性耳下腺炎と成人発症の睾丸炎を合併した流行性耳下腺炎を報告した.男性不妊になる可能性もあるので,予防法の確立が望まれる.
• NAID 110006200570

Related Pictures

---

★リンクテーブル★

リンク元	「おたふく風邪」
拡張検索	「epidemic parotitis virus」
関連記事	「epidemic」

「おたふく風邪」

　　[★]

英

mumps、epidemic parotitis

関

流行性耳下腺炎、ムンプス

「epidemic parotitis virus」

　　[★] 流行性耳下腺炎ウイルス

「epidemic」

　　[★]

日

• adj.

• 流行性の、伝染性の

• n.

• 流行病、流行

関